Skip to content

Clinical trials

Observational Scleroderma, Systemic trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Scleroderma, Systemic Phase: Observational Clear all

147 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20052
20061
20075
20083
20092
20102
20113
20123
20137
20144
20153
20167
20175
20189
20197
20207
202113
202210
202312
202414
202514
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed57
Recruiting35
Unknown status29
Not yet recruiting11
Withdrawn5
Enrolling by invitation5
Terminated4
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University Hospital, Lille9
Assistance Publique - Hôpitaux de Paris7
Assiut University7
Central Hospital, Nancy, France5
Hacettepe University4
University Hospital, Strasbourg, France4
Duke University3
Meir Medical Center3
Seoul National University Hospital3
University Hospital, Brest3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Scleroderma, Systemic147
Scleroderma, Diffuse21
Lupus Erythematosus, Systemic18
Arthritis, Rheumatoid17
Lung Diseases, Interstitial14
Hypertension, Pulmonary10
Sjogren's Syndrome9
Autoimmune Diseases8
Pulmonary Arterial Hypertension8
Connective Tissue Diseases7

Trials

Showing 51 to 75 of 147. Each trial links to its page on Pharma Observatory.

47 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.